Literature DB >> 18054665

Cryoablation in the musculoskeletal system.

Steven R Ullrick1, Jeffrey J Hebert, Kirkland W Davis.   

Abstract

Pain palliation can be challenging in patients with metastases to the musculoskeletal system, and conventional therapy can be less than optimal for pain management. Recent advances in technology have allowed for the addition of image-guided ablation to the armamentarium for treating musculoskeletal metastases. This article focuses on one such technique, percutaneous cryoablation, and the experiences with this technique at the authors' institution. After a brief review of the history and theory behind cryoablation, the basic technique of percutaneous cryoablation of musculoskeletal metastases is described. This is followed by a review of the cases that have been performed at the authors' institution. A discussion on the many advantages and relatively few disadvantages of this exciting new technique is then put forth. Percutaneous cryoablation is beginning to emerge as a useful method of image-guided ablation of musculoskeletal metastases. As data continue to mount on this exciting application of new technology, image-guided cryoablation of musculoskeletal metastases appears to hold much promise in the treatment of pain related to these lesions.

Entities:  

Mesh:

Year:  2008        PMID: 18054665     DOI: 10.1067/j.cpradiol.2007.05.001

Source DB:  PubMed          Journal:  Curr Probl Diagn Radiol        ISSN: 0363-0188


  3 in total

1.  Percutaneous bone tumor management.

Authors:  Afshin Gangi; Xavier Buy
Journal:  Semin Intervent Radiol       Date:  2010-06       Impact factor: 1.513

2.  CT-guided percutaneous cryoablation of osteoid osteoma in children: an initial study.

Authors:  Bin Wu; Yue-Yong Xiao; Xiao Zhang; Lei Zhao; John A Carrino
Journal:  Skeletal Radiol       Date:  2011-02-12       Impact factor: 2.199

Review 3.  State-of-the-art of minimally invasive treatments of bone metastases.

Authors:  Cun Li; Qianghua Wu; Daijun Chang; Hui Liang; Xiaofei Ding; Chendeng Lao; Zonggui Huang
Journal:  J Bone Oncol       Date:  2022-03-19       Impact factor: 4.072

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.